Published: 14 June 2019
Author(s): Antonio Tursi, Giammarco Mocci, Roberto Faggiani, Leonardo Allegretta, Nicola Della Valle, Antonio de Medici, Giacomo Forti, Marilisa Franceschi, Antonio Ferronato, Sara Gallina, Giuseppina Grasso, Tiziana Larussa, Francesco Luzza, Roberto Lorenzetti, Antonio Penna, Stefano Rodino', Ladislava Sebkova, Angelo Lauria, Simona Piergallini, Giuseppe Pranzo, Stefano Scorza, Costantino Zampaletta, Marcello Picchio, Walter Elisei
Section: Original Article
Italian data currently available in managing ulcerative colitis (UC) and Crohn's disease (CD) patients with vedolizumab (VDZ) are coming just from secondary and tertiary centers. The present study aimed to assess the real-life efficacy and safety of VDZ to achieve remission in inflammatory bowel diseases (IBD) outpatients in primary gastroenterology centers.
